10-KPeriod: FY2024

DEXCOM INC Annual Report, Year Ended Dec 31, 2024

Filed February 18, 2025For Securities:DXCM

Summary

DexCom, Inc. (DXCM) has demonstrated robust performance in its latest annual report, driven by strong growth in its continuous glucose monitoring (CGM) systems. The company reported significant revenue growth, primarily fueled by increased sales volumes of its disposable sensors, indicating a growing global customer base. This expansion was supported by the launch of its Stelo biosensor in August 2024, targeting the prediabetes and Type 2 diabetes non-insulin user market, marking an entry into the over-the-counter space. Despite increased cost of sales due to higher volume and freight costs, the company managed to grow its gross profit, though gross profit margin saw a slight decrease. Overall, Dexcom maintained operating income and saw a notable increase in operating cash flow, reflecting effective operational management and continued demand for its innovative diabetes management solutions.

Financial Highlights

52 data points
Beta

Revenue

$4.03B

60.5% Gross Margin

Net Income

$576.20M

14.3% Net Margin

EPS (Diluted)

$1.42

Total Assets

$6.48B

Cash & Equivalents

$606.10M

Free Cash Flow

$630.70M

Financial Statements
Beta
Revenue$4.03B
Cost of Revenue$1.59B
Gross Profit$2.44B
R&D Expenses$552.40M
SG&A Expenses$1.29B
Operating Expenses$1.84B
Operating Income$600.00M
Interest Expense$14.90M
Net Income$576.20M
EPS (Basic)$1.46
EPS (Diluted)$1.42
Shares Outstanding (Basic)393.60M
Shares Outstanding (Diluted)412.70M

Key Highlights

  • 1Revenue increased by 11% year-over-year to $4.03 billion, driven by strong sales volume of disposable sensors.
  • 2Gross profit increased by 7% year-over-year to $2.44 billion, although gross profit margin decreased slightly due to product mix, higher freight costs, and inventory charges.
  • 3Operating income remained stable at $600.0 million, showing consistent operational performance.
  • 4Net income grew by 6% to $576.2 million, reflecting solid profitability.
  • 5Operating cash flow saw a significant increase of 32% to $989.5 million, indicating strong cash generation.
  • 6Launched Stelo, an over-the-counter glucose biosensor, in August 2024, expanding into a new market segment.
  • 7Manufacturing and inventory challenges for the G7 system were noted, potentially impacting supply in certain markets.

Frequently Asked Questions

Dexcom's primary products are continuous glucose monitoring (CGM) systems, including the Dexcom G6, G7, and Dexcom ONE systems, designed for diabetes management. They also recently launched Stelo, an over-the-counter glucose biosensor targeting adults with prediabetes and Type 2 diabetes who do not use insulin. The company focuses on patients, caregivers, and clinicians globally.

For the twelve months ended December 31, 2024, Dexcom reported revenue of $4.03 billion, an 11% increase year-over-year. Gross profit was $2.44 billion (a 7% increase), operating income was $600.0 million (a 0.4% increase), and net income was $576.2 million (a 6% increase). Operating cash flow increased significantly by 32% to $989.5 million.

Key growth drivers include the increasing adoption of CGM technology, expansion into new markets and patient populations (like prediabetes), and product innovation such as the Stelo biosensor. Challenges include pricing pressures from payors, manufacturing and inventory issues impacting supply, competition from established players, and the complex regulatory environment for medical devices.

Dexcom has acknowledged recent manufacturing and inventory challenges, particularly with the G7 system, which have led to supply disruptions. While working to remedy these issues, the company is also investing in expanding its manufacturing capacity, including new facilities in Malaysia and Ireland, to support future demand.